Compare Nuscale Power Corporation (SMR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuscale Power Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? Nuscale Power Corporation trades at $8.09 (market cap $2.76B), while Vertex Pharmaceuticals Incorporated trades at $478.54 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 44.2× Nuscale Power Corporation's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| SMR | VRTX | |
|---|---|---|
Market Cap | $2.76B | $121.95B |
Sector | Utilities | Health |
52-Week High | $53.43 | $529.59 |
52-Week Low | $7.64 | $366.54 |
Enterprise Value | $1.87B | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMR (NuScale Power) trades at $7.96, up 3.2% today but remains in a bearish technical trend. The company faces severe financial strain with a net income margin of -2,066.55% and negative cash flow from operations of $459.61M in 2025. Recent earnings misses and high cash burn highlight execution risks, yet analyst consensus suggests 54% upside to a $12.25 price target, with 50% of coverage rating the stock a Buy amid optimism for its small modular reactor technology.
The stock presents a high-risk, high-reward opportunity. Long-term potential hinges on commercializing its nuclear technology, but near-term risks include persistent losses, funding needs, and project delays. Investors must weigh the speculative growth narrative against fundamental weaknesses and high volatility.
Vertex Pharmaceuticals (VRTX) trades at $480.51, down 1.06% on the day, with a bullish technical signal driven by moving averages. The stock shows strong profitability with a 35.51% net income margin and robust cash flow, though it faces a recent earnings miss. A major $10 billion acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology portfolio, adding potential for significant future revenue growth.
The outlook remains positive with an 85.71% analyst buy rating and a $538 consensus price target, implying 12% upside. Key risks include integration challenges from the acquisition and reliance on cystic fibrosis treatments. Earnings growth and successful pipeline execution are critical catalysts for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
